Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of ipilimumab plus paclitaxel/carboplatin in stage IV or recurrent NSCLC
jRCT2080222115Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing Ipilimumab + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms).
02
Drugs
ipilimumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2080222115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222115.